AMENDMENTS TO THE CLAIMS

1. (Original) Combined pharmaceutical preparation containing G-CSF and P1GF as the active substances, for use in the mobilization of blood stem cells in a patient or subject in need thereof.

2. (Currently Amended) Combined preparation according to claim 1, wherein G-CSF and P1GF are simultaneously ~~or separately~~ administered to said patient or subject.

3. (Currently Amended) Combined preparation according to ~~claims 1-2~~ claim 1, for parenteral administration.

4. (Currently Amended) Combined preparation according to ~~claims 1-3~~ claim 1, containing recombinant hG-CSF and rhPlGF.

5. (Currently Amended) Combined preparation according to ~~claims 1-4~~ claim 1, containing from 1 to 150 μg/kg G-CSF and from 10 to 300 μg/kg P1GF.

6. - 10 (Canceled)

11. (New) A method for treating a state, condition or disease selected from the group consisting of organ or cell transplantation, tumor chemo-radiotherapy, autologous stem cell transplantion and allogeneic stem cell transplantation, in a patient presenting with non-Hodgkin lymphoma (NHL), relapsed Hodgkin lymphoma (HL), multiple myeloma, or the recovery phase following

myelosuppressive chemotherapy, comprising administering the combined pharmaceutical preparation of claim 1 to said patient.

12. (New) The method according to claim 11, wherein the combined pharmaceutical preparation provides a daily amount of 10 μg/kg G-CSF and of 130 μg/kg P1GF.

13. (New) The method according to claim 11, in which the combined pharmaceutical preparation is administered parenterally.

14. (New) The method according to claim 12, in which the combined pharmaceutical preparation is administered parenterally.

15. (New) The combined preparation according to claim 1, wherein G-CSF and P1GF are separately administered to said patient or subject.

16. (New) The combined preparation according to claim 15, for parenteral administration.

17. (New) The combined preparation according to claim 2, for parenteral administration.